• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 4. Exciting clusters, what does off-resonance actually mean??
  Goonay Yousefalizadeh,Shideh Ahmadi,Nicholas J. Mosey,Kevin G. Stamplecoskie Nanoscale, 2021,13, 242-252
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Thienopyrimidines

7-BROMO-2-METHOXYTHIENO[3,2-D]PYRIMIDINE (CAS No. 1259978-35-2): A Key Intermediate in Modern Pharmaceutical Research

7-BROMO-2-METHOXYTHIENO[3,2-D]PYRIMIDINE, a compound with the CAS number 1259978-35-2, has emerged as a crucial intermediate in the realm of pharmaceutical research and drug development. This heterocyclic compound, featuring a thiophene-pyrimidine core structure, has garnered significant attention due to its versatile applications in synthesizing biologically active molecules. The presence of both bromo and methoxy substituents on the thiophene ring enhances its reactivity, making it an invaluable building block for medicinal chemists.

The structural motif of 7-BROMO-2-METHOXYTHIENO[3,2-D]PYRIMIDINE is particularly noteworthy for its potential in modulating various biological pathways. The thiophene ring, known for its stability and aromaticity, provides a scaffold that can be easily modified through nucleophilic substitution reactions. This characteristic is exploited in the synthesis of novel therapeutic agents targeting a wide range of diseases, including cancer and inflammatory disorders.

In recent years, there has been a surge in research focused on developing small-molecule inhibitors that disrupt key signaling pathways involved in disease progression. Among these pathways, the Janus Kinase (JAK) signaling pathway has been extensively studied due to its role in autoimmune diseases and cancer. Compounds derived from thiophene-pyrimidine scaffolds, such as 7-BROMO-2-METHOXYTHIENO[3,2-D]PYRIMIDINE, have shown promise as JAK inhibitors. For instance, modifications of this core structure have led to the discovery of potent JAK1 and JAK2 inhibitors that exhibit high selectivity and low toxicity.

The bromo substituent at the 7-position of the thiophene ring is particularly significant as it serves as a versatile handle for further functionalization. Through palladium-catalyzed cross-coupling reactions such as Suzuki or Buchwald-Hartwig couplings, this bromo group can be replaced with aryl or amino groups, respectively. This allows for the construction of more complex molecular architectures with tailored biological activities. Additionally, the methoxy group at the 2-position influences the electronic properties of the ring, enhancing its interaction with biological targets.

One of the most compelling aspects of 7-BROMO-2-METHOXYTHIENO[3,2-D]PYRIMIDINE is its role in generating novel kinase inhibitors. Kinases are enzymes that play a critical role in cell signaling and are often dysregulated in diseases such as cancer. By designing molecules that selectively inhibit specific kinases, researchers aim to develop treatments that disrupt abnormal signaling pathways without affecting normal cellular processes. The pyrimidine moiety in this compound mimics ATP binding sites on kinases, thereby blocking their activity.

The synthesis of 7-BROMO-2-METHOXYTHIENO[3,2-D]PYRIMIDINE involves multi-step organic transformations that highlight its synthetic utility. Starting from commercially available precursors such as 2-methoxythiophene-3-carboxylic acid or its derivatives, various functional groups can be introduced through sequential reactions. For example, lithiation followed by bromination provides a straightforward route to introduce the bromo substituent at the desired position. Subsequent nucleophilic aromatic substitution or metal-catalyzed coupling reactions then allow for further diversification of the scaffold.

In clinical research, derivatives of thiophene-pyrimidine compounds have shown significant promise in preclinical studies. These studies often focus on evaluating the pharmacokinetic properties and therapeutic efficacy of novel compounds. The structural features of 7-BROMO-2-METHOXYTHIENO[3,2-D]PYRIMIDINE, including its solubility and metabolic stability, make it an attractive candidate for further development into a drug candidate. Additionally, computational modeling techniques have been employed to predict how different substituents might affect binding affinity and selectivity.

The versatility of 7-BROMO-2-METHOXYTHIENO[3,2-D]PYRIMIDINE extends beyond kinase inhibition. Its scaffold has also been explored in the development of antiviral and anti-inflammatory agents. For instance, modifications of this compound have led to the discovery of molecules that inhibit viral proteases or modulate inflammatory cytokine production. These findings underscore its potential as a starting point for designing therapeutics against a variety of diseases.

The growing interest in heterocyclic compounds like thiophene-pyrimidines underscores their importance in modern drug discovery. The ability to modify these scaffolds in multiple ways allows researchers to fine-tune their properties for specific applications. As our understanding of biological pathways continues to expand, compounds derived from structures similar to 7-BROMO-2-METHOXYTHIENO[3,2-D]PYRIMIDINE will undoubtedly play a pivotal role in developing next-generation therapeutics.

In conclusion, 7-BROMO-2-METHOXYTHIENO[3,2-D]PYRIMIDINE (CAS No. 1259978-35-2) represents a valuable intermediate in pharmaceutical research with broad applications across multiple therapeutic areas. Its unique structural features and reactivity make it an ideal candidate for generating novel biologically active molecules. As research progresses, this compound will continue to contribute to advancements in drug discovery and development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)